Literature DB >> 21327902

A tipping point in drug dosing in late-life schizophrenia.

Takashi Tsuboi1, Takefumi Suzuki, Hiroyuki Uchida.   

Abstract

Minimally effective doses of antipsychotics are likely influenced by several clinical and demographic characteristics of patients, with age being one of the most important elements. In light of age-related physiologic changes as well as interindividual differences in pharmacokinetic and pharmacodynamic systems, individualized dosing with regard to age will be critically important for safer drug treatment for older patients with schizophrenia. In the present review, we propose the following cautious psychopharmacologic interventions for this population: 1) simple regimen (avoid polypharmacy), 2) be aware of the presence of patients who are very sensitive to drugs, 3) gradual dose titration, and 4) timely and thorough assessments of therapeutic and side effects. The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327902     DOI: 10.1007/s11920-011-0189-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  69 in total

Review 1.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.

Authors:  Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2005       Impact factor: 4.132

2.  Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.

Authors:  D V Jeste; A Okamoto; J Napolitano; J M Kane; R A Martinez
Journal:  Am J Psychiatry       Date:  2000-07       Impact factor: 18.112

3.  Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.

Authors:  Jacobo Mintzer; Andrew Greenspan; Ivo Caers; Ilse Van Hove; Stuart Kushner; Myron Weiner; Georges Gharabawi; Lon S Schneider
Journal:  Am J Geriatr Psychiatry       Date:  2006-03       Impact factor: 4.105

4.  Physical comorbidity and polypharmacy in older psychiatric patients.

Authors:  J P Lacro; D V Jeste
Journal:  Biol Psychiatry       Date:  1994-08-01       Impact factor: 13.382

5.  Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Pierre N Tariot; Lon Schneider; Ira R Katz; Jacobo E Mintzer; Jamie Street; Margaret Copenhaver; Celeste Williams-Hughes
Journal:  Am J Geriatr Psychiatry       Date:  2006-08-11       Impact factor: 4.105

6.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Authors:  J S Street; W S Clark; K S Gannon; J L Cummings; F P Bymaster; R N Tamura; S J Mitan; D L Kadam; T M Sanger; P D Feldman; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-10

Review 7.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

9.  Susceptibility to neuroleptic-induced parkinsonism--age and increased substantia nigra echogenicity as putative risk factors.

Authors:  Burkhard Emanuel Jabs; Andreas Joachim Bartsch; Bruno Pfuhlmann
Journal:  Eur Psychiatry       Date:  2003-06       Impact factor: 5.361

10.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.